To include your compound in the COVID-19 Resource Center, submit it here.

Aldoxorubicin: Phase Ib started

CytRx began an open-label, dose-escalation Phase Ib trial to evaluate 170, 250 and 350 mg/m 2

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE